Similarly, imatinib treatment significantly increased miR-181a expression in CML CD34+ cells (n = 10) (Fig. 1G), though the extent was not as strong as that in K562 cells treated with NL. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.